Comprehensive Monitoring for Medical Devices
September 13-15, 2016
Boston, MA
Effectively Writing Clinical Trial Protocols
September 14-15, 2016
Boston, MA
Clinical Project Management: Advanced
September 6-7, 2016
San Diego, CA
Monitoring Clinical Drug Studies: Beginner
September 6-8, 2016
San Francisco, CA

Implications of the New FDA Guideline for a Risk-Based Approach to Monitoring October 2011

Course Description

The FDA’s Guideline for the Monitoring of Clinical Investigations (1988-2010) has been removed from the FDA list of guidance documents. Instead, FDA has released an updated version of the  Bioresearch Monitoring (BIMO) Compliance Program Guidance Manual for Sponsor/CRO and Monitoring, and most recently the agency released a draft guidance to reflect their expectations and recommendations related to monitoring investigation sites, monitoring systems, and investigative site oversight. In this web seminar, we will discuss the content and the implications to sponsor monitoring and clinical investigation sites.


Learning Objectives

  • Explain ways in which the regulatory climate is reflected in the new monitoring guideline
  • Discuss the content of the guideline in relation to traditional monitoring plans
  • Assess the implications of the guideline to current monitoring practices and relationships with oversight of Clinical Investigator

Who Should Attend

  • Clinical Research Associates
  • Study and CRA Managers
  • Clinical Investigators and Staff
  • Sponsor/CROs Clinical Operations
  • Clinical Quality Compliance and Quality Assurance Professionals


Sandra “SAM” Sather, M.S., B.S.N., C.C.R.A., C.C.R.C. 

Click here for complete trainer biographies 

Course Length Time

1.5 hours; 9:00 - 10:30 a.m. Eastern

Course Dates

October 18, 2011

Hold this course at your company!
For more information, contact Naila Ganatra at (215) 413-2471.